SK Biopharmaceuticals (326030) — Cenobamate Growth Trajectory and 2026 Valuation Analysis
SK Biopharmaceuticals (326030) is a pharmaceutical/biopharmaceutical company that directly markets cenobamate (U.S. brand name: XCOPRI) — a domestically developed third-generation epilepsy drug — in the United States. Based on the preliminary Q1 2026 earnings disclosure (2026-05-07), operating income reached 898억원 (≈$59.9M) (YoY +249.7%), signaling visible profitability improvement. At the current price of 99,200원 (≈$66.2) as of 2026-05-13, the stock trades at Trailing PER 29.1x and Forward PER*1 23.0x — below the sector average.
1. Corporate Overview and Core Business
SK Biopharmaceuticals is a CNS/epilepsy specialty pharmaceutical company affiliated with SK Inc., listed on the KOSPI (ticker: 326030). Its flagship product is cenobamate, a third-generation antiepileptic drug marketed in the United States under the brand name XCOPRI, with a direct-sales model in the U.S. market. On a consolidated basis for 2025, revenue reached 7,067억원 (≈$471.8M) (YoY +29.0%) and operating profit was 2,039억원 (≈$136.1M) (OPM 28.9%), marking entry into a profit growth phase following its turnaround to profitability. In Q1 2026, the company reported operating profit of 898억원 (≈$59.9M) (YoY +249.7%) based on its preliminary earnings disclosure (2026-05-07). Based on the current share price of KRW 99,200 (≈$66.2) as of 2026-05-13, market capitalization stands at approximately 7.0조원 (≈$4.7B).
📌 Q1 2026 operating profit 898억원 (≈$59.9M) (YoY +249.7%), market cap 7.0조원 (≈$4.7B) (as of 2026-05-13)
2. Core Product Competitive Analysis
Cenobamate is an FDA-approved novel antiepileptic drug with a consistently growing patient base in the United States quarter over quarter. The company's 2026 guidance projects XCOPRI U.S. net sales of $550M–$580M*2. In February 2026, the patent expiration of Briviact (brivaracetam), the leading competing drug, opened a prescription conversion window, and the U.S. NDA submission for a suspension formulation has expanded the potential for pediatric and primary generalized seizure indications. Geographic expansion is underway through the full-scale commercial launch in Korea and the anticipated H2 2026 regulatory approval and launch in Japan.
| Category | Details |
|---|---|
| Position | Sole U.S. direct sales of cenobamate, a third-generation antiepileptic drug; independently developed new drug |
| Competitive Advantages | Compound patent valid through 2032; entering prescription conversion window following Briviact patent expiration (Feb 2026); suspension formulation NDA submission completed |
| Competitive Disadvantages | High revenue dependence on a single product; no second product secured; new pipeline candidates remain in early preclinical/Phase 1 clinical stages |
3. Valuation Analysis
As of 2026-05-13, the current price of KRW 99,200 implies a Trailing PER of 29.1x, slightly below the sector average of 29.4x. Based on the 2026 consensus EPS, the Forward PER*1 stands at 23.0x, 5.7 percentage points below the sector average Forward PER of 28.7x. The combination of PBR 9.55x and ROE 30.6% indicates that strong profitability underpins the valuation premium. A debt-to-equity ratio of 45.0% reflects near-debt-free financial soundness. The downward trajectory from Trailing to Forward PER suggests that the pace of earnings growth supports the current share price level.
📌 Forward PER of 23.0x is 5.7 percentage points below the sector average of 28.7x, indicating an undervaluation structure driven by earnings growth
| Metric | Current | Sector Avg. | Interpretation |
|---|---|---|---|
| Trailing PER | 29.1x | 29.4x | Slightly undervalued vs. sector |
| Forward PER*1 | 23.0x | 28.7x | 5.7 ppts below sector |
| PBR | 9.55x | — | Profitability-driven premium |
| ROE | 30.6% | — | Solid return on equity |
| Debt-to-Equity | 45.0% | — | Sound financial health |
4. Risks & Monitoring Points
The actual pace of SG&A spending against the guidance (up to 5,700억원 (≈$380.5M) annually) is the key variable driving quarterly earnings volatility. The cenobamate compound patent is valid through 2032, but litigation with U.S. generic developers is ongoing. The second product launch has been delayed for several years, and new pipeline candidates remain in preclinical or early clinical stages. Given the high proportion of USD-denominated revenue, KRW/USD exchange rate fluctuations directly affect reported sales and earnings.
- ⚠️ Cenobamate generic litigation — risk of early market entry attempt before compound patent expiry in 2032
- ⚠️ Second product launch delay — prolonged single-product dependency amplifies pipeline risk
- ⚠️ KRW/USD appreciation — high USD revenue exposure leads to direct reduction in translated sales and earnings
- 📌 U.S. total prescription volume (TRx) monthly trend — whether quarterly growth of +3% or more is sustained
- 📌 Quarterly actual SG&A spend — execution rate against annual guidance of 5,700억원 (≈$380.5M)
- 📌 Any disclosures related to second product licensing or partnership negotiations
5. Recent DART Disclosures
Two disclosures submitted in May 2026 — the preliminary earnings disclosure and the IR event notice — are directly relevant to this analysis. Ownership-change filings (National Pension Service bulk holdings report, SK share change report) were excluded as they have limited direct relevance to the business content of this report.
| 날짜 | 공시명 | 요약 |
|---|---|---|
| 2026-05-07 | Consolidated Financial Statements Based Operating (Preliminary) Results (Fair Disclosure) | Preliminary consolidated operating results for Q1 2026. Operating profit of 898억원 (≈$59.9M) (YoY +249.7%) confirms that cenobamate U.S. revenue growth has translated into profitability. |
| 2026-05-04 | Investor Relations (IR) Event Notice (Guidance Disclosure) | Disclosure announcing the scheduling of an investor relations (IR) event in May 2026, aimed at presenting current business status and pipeline strategy. |
SK Biopharmaceuticals is building a below-sector-average valuation on a Forward PER basis, underpinned by expanding cenobamate prescriptions and improving profitability. The pace of SG&A spending, progress of its 2nd product pipeline, and U.S. prescription volume (TRx) data are the key variables for future earnings.
📎 출처 및 추정 근거
- *1 Based on 2026 consensus Forward EPS. TradeAlert DB as of 2026-05-13; current price 99,200원 (≈$66.2) / Forward PER 23.0x applied.
- *2 SK Biopharmaceuticals 4Q25 earnings release (2026.03) and Hana Securities April 2026 report citing company annual guidance. Dollar revenue target: $550M–$580M.
- *3 USD equivalents (≈$) are approximate, calculated at 1 USD = 1,498 KRW (as of 2026-05-16, source: Yahoo Finance via TradeAlert).
본 보고서는 정보 제공 목적이며 투자 권유가 아닙니다. 투자 결정은 본인 책임입니다.
댓글 없음:
댓글 쓰기